Niagen Bioscience Inc(NAGE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:52 PM ET (Korea 9/12 08:52)
Full metrics table
| Index | RUT | P/E | 16.15 | EPS (ttm) | 0.19 | Insider Own | 34.11% | Shs Outstand | 78.9M | Perf Week | -2.25% |
| Market Cap | 0.24B | Forward P/E | 19.62 | EPS next Y | 7.46% | Insider Trans | - | Shs Float | 52.1M | Perf Month | -0.65% |
| Enterprise Value | 0.18B | PEG | 2.54 | EPS next Q | 0.02 | Inst Own | 41.16% | Short Float | 7.97% | Perf Quarter | -11.37% |
| Income | 0.02B | P/S | 1.86 | EPS this Y | -27.9% | Inst Trans | -8.49% | Short Ratio | 6.51 | Perf Half Y | -36.93% |
| Sales | 0.13B | P/B | 2.91 | EPS next 5Y | 7.72% | ROA | 16.14% | Short Interest | 4.16M | Perf YTD | -52.2% |
| Book/sh | 1.05 | P/C | 3.6 | EPS past 3/5Y | - | ROE | 21.8% | 52W High | -71.1% ($10.52) | Perf Year | -68.4% |
| Cash/sh | 0.84 | P/FCF | 42.8 | Sales past 3/5Y | 21.56% 16.91% | ROIC | 19.05% | 52W Low | 5.92% ($2.87) | Perf 3Y | 99.34% |
| Dividend Est. | - | EV/EBITDA | 16.6 | EPS Y/Y TTM | -12.12% | Gross Margin | 64.24% | Volatility(W/M) | 2.97% 3.23% | Perf 5Y | -60.31% |
| Dividend TTM | - | EV/Sales | 1.36 | Sales Y/Y TTM | 10.99% | Oper. Margin | 6.67% | ATR (14) | 0.11 | Perf 10Y | -5% |
| Dividend Ex-Date | - | Quick Ratio | 5.13 | EPS Q/Q | -72.01% | Profit Margin | 12.39% | RSI (14) | 42.04 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.5 | Sales Q/Q | -4.28% | SMA20 | -3.28% ($3.14) | Beta | 2.01 | Target Price | $12.08 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/8/4 | SMA50 | -6.1% ($3.24) | Rel Volume | 0.5 | Prev Close | $3.04 |
| Employees | 117 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 20.48% -2.45% | SMA200 | -33.7% ($4.59) | Avg Volume(3M) | 0.64M | Price | $3.04 |
| IPO | 2008/6/24 | Option/Short | Yes/Yes | Trades | 2359 | Volume | 321,475 | Change | 0.16% |
Company
NAGE is a Consumer Defensive sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 NiaGenesis Biosciences (NAGE) is a science-driven nutraceutical company focused on aging-related health. Founded in 1999 and formerly known as ChromaDex, it is a US-based company that operates consumer products, ingredients, and analytical reference standards businesses centered on Niagen, an NAD precursor ingredient and a key intracellular coenzyme.
Over the past 1 year, on the lower side
71% below its 1-year high.
NAGE makes money exceptionally well
6.67% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -27.9% this year.
Tap to view numbers
The price looks about right
Trading at 16.1 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +99.3% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 41.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
LOPP 0.00%
QQQS 0.00%
SQLV 0.00%
BFOR 0.00%
SFLO 0.00%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
GRID 11.8B
WATS -It ranks #4 in the industry
Based on market cap of $241M.
NAGE $241M PER 16.1
KHC $29B PER -
GIS $19B PER -
MKC $14B PER 8.5
FAQ
What kind of company is NAGE?
NAGE belongs to the Consumer Defensive sector and operates in the Packaged Foods industry.
What is the market cap of NAGE?
The market cap of NAGE is approximately $241M, ranking 3,955 within its sector.
What is the P/E ratio of NAGE?
NAGE has a P/E ratio of approximately 16.1x, which can be used to assess its valuation relative to the Consumer Defensive sector average.
What is the 52-week high and low for NAGE?
NAGE has recorded a 52-week high of $10.52 and a low of $2.87.
